Skip to main content
main-content

Neurology

ECTRIMS 2019

medwireNews attended ECTRIMS 2019 in Stockholm. Watch our expert interviews on the major trials.

Expert interviews from ECTRIMS 2019

13-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Sustained reduction in disability progression with ocrelizumab in patients with primary progressive MS

Jerry Wolinsky discusses findings from the open-label extension phase of the phase III ORATORIO trial highlighting the benefits of early ocrelizumab treatment on disability progression in patients with primary progressive multiple sclerosis (10:24).

13-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Support for newer drug-modifying therapies in initial treatment of paediatric MS

Kristen Krysko gives her findings on the real-world effectiveness of newer and injectable drug-modifying therapies as a guide to which treatments to initiate in children with multiple sclerosis (3:06).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Myelin-specific CD8+ T-cell activation increased in MS

Joseph Sabatino discusses research showing a unique multiple sclerosis phenotype in the form of increased myelin-specific CD8+ T-cell activation and a role for anti-CD20 therapy (5:15).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Perivascular inflammation and active white matter lesions linked to rapid MS progression

Damiano Marastoni explains how factors involved in white matter chronic inflammation play a key role in rapid MS disease progression (2:26).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Prolonged exposure to disease-modifying therapies reduces the risk for disability progression in RRMS

Giuseppe Lucisano reports real-world data showing protection against disability progression in patients with relapsing-remitting multiple sclerosis over more than 10 years of follow-up (3:19).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Timely and continuous therapy reduces conversion to progressive MS

Pietro Iaffaldano comments on real-world data showing risk factors associated with increased conversion from relapsing-remitting multiple sclerosis to secondary progressive disease (4:31).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Hypogammaglobulinemia risk increased with rituximab in MS

Susanna Hallberg highlights hypogammaglobulinaemia as an important side effect of long-term rituximab treatment in MS, and makes recommendations on how to manage it in patients (2:32).

02-05-2019 | Rheumatology | News | Article

Multifactorial nature of cognitive dysfunction highlighted in SLE

Poor attenuation of the default mode network regions of the brain may contribute to cognitive impairments in patients with systemic lupus erythematosus, say UK researchers.

Twitter Icon Follow medwireNews

Click here
Image Credits